Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00974610|
Recruitment Status : Completed
First Posted : September 10, 2009
Last Update Posted : May 24, 2017
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in peptides and proteins and identify biomarkers related to cancer.
PURPOSE: This research study is looking at blood samples from patients with malignant melanoma, metastatic breast cancer, advanced lung cancer, pancreatic cancer, or colorectal cancer.
|Condition or disease|
|Breast Cancer Colorectal Cancer Lung Cancer Melanoma (Skin) Pancreatic Cancer|
- To assess which potential peptide and protein markers produced by human melanoma, lung, breast, pancreatic, and colorectal cell lines may be detectable in serum of patients from these five disease groups.
- To conduct further extensive investigation with respect to identification of the protein/peptide involved, determination of specificity for each cancer, and development of more sensitive assays to look for such markers in a wider population of patients, including those undergoing therapy.
OUTLINE: This is a multicenter study.
Blood samples are collected before surgical intervention or treatment to assess peptide and protein markers.
|Study Type :||Observational|
|Actual Enrollment :||803 participants|
|Official Title:||Collaborative Project on Potential Serum Markers for Malignant Melanoma, Metastatic Breast, Advanced Lung Pancreatic Carcinoma and Colorectal Cancer|
|Study Start Date :||August 2008|
|Primary Completion Date :||December 2015|
|Study Completion Date :||January 2017|
- Detection of peptide and protein markers in serum [ Time Frame: Ongoing ]
- Identification of the protein/peptide involved [ Time Frame: Ongoing ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00974610
|Cork University Hospital|
|Mercy University Hospital|
|Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital|
|Dublin, Ireland, 24|
|St. Vincent's University Hospital|
|Dublin, Ireland, 4|
|Mater Misericordiae University Hospital|
|Dublin, Ireland, 7|
|St. James's Hospital|
|Dublin, Ireland, 8|
|Dublin, Ireland, 9|
|Mater Private Hospital|
|St Luke's Hospital|
|University College Hospital|
|Letterkenny General Hospital|
|Mid-Western Cancer Centre at Mid-Western Regional Hospital|
|Limerick, Ireland, 0009|
|Waterford Regional Hospital|
|Principal Investigator:||Martin Clynes||National Institute for Cellular Biotechnology at Dublin City University|